Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Tocagen Granted ApolloBio Greater China Rights of Immunotherapy Candidate for $127 Million

publication date: Apr 23, 2018

Tocagen Inc. licensed its Phase III stage candidate Toca 511 & Toca FC to ApolloBio. The deal includes an upfront payment of $16 million, a near-term $4 million milestone after clinical trials and other additional future payments totaling up to $107 million. The deal is worth of $127 million in total. According to the deal terms, ApolloBio will gain exclusive rights of Toca 511 & Toca FC and will be responsible for developing and commercializing the candidate in Greater China, including mainland China, Hong Kong, Macao and Taiwan. More details....

Stock Symbol: (Nasdaq: TOCA) (NEEQ: 430187)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China